Dual blockade of epidermal growth factor receptor and insulin‐like growth factor receptor–1 signaling in metastatic pancreatic cancer: Phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727)

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|120|19|2980-2985

ISSN： 0008-543x

Source： CANCER, Vol.120, Iss.19, 2014-10, pp. : 2980-2985

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical Significance of Insulin-Like Growth Factor Type 1 Receptor and Epidermal Growth Factor Receptor in Patients with Advanced Gastric Cancer

By  

Oncology, Vol. 74, Iss. 1-2, 2008-06 ,pp. : 76-83

Karger

Access to resources Recommend Favorite

Relationships of Insulin-Like Growth Factor-1 Receptor and Epidermal Growth Factor Receptor Expression to Clinical Outcomes in Patients with Colorectal Cancer

By  

Oncology, Vol. 76, Iss. 1, 2008-11 ,pp. : 42-48

Karger

Access to resources Recommend Favorite

Shikonin and its derivatives inhibit the epidermal growth factor receptor signaling and synergistically kill glioblastoma cells in combination with erlotinib

By  

INTERNATIONAL JOURNAL OF CANCER, Vol. 137, Iss. 6, 2015-09 ,pp. : 1446-1456

John Wiley & Sons Inc

Access to resources Recommend Favorite

Delay of treatment change after objective progression on first‐line erlotinib in epidermal growth factor receptor‐mutant lung cancer

By  

CANCER, Vol. 121, Iss. 15, 2015-08 ,pp. : 2570-2577

John Wiley & Sons Inc

Access to resources Recommend Favorite

Patient‐reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T‐DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2–positive locally advanced or metastatic breast cancer

By  

CANCER, Vol. 120, Iss. 5, 2014-03 ,pp. : 642-651

John Wiley & Sons Inc

Access to resources Recommend Favorite